Antibody drug conjugates

Patent metadata

Field	Value
Publication number	US-10005836-B2
Application number	US-201514940961-A
Country	US
Kind code	B2
Filing date	Nov 13, 2015
Priority date	Nov 14, 2014
Publication date	Jun 26, 2018
Grant date	Jun 26, 2018

Abstract

This application discloses anti-P-cadherin antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments. The invention also relates to methods of treating cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.

First claim

We claim:

1. An antibody or antigen binding fragment thereof that binds P-cadherin comprising:
a. a heavy chain variable region (VH) that comprises a VH CDR1 of SEQ ID NO: 1, a VH CDR2 of SEQ ID NO: 2, and a VH CDR3 of SEQ ID NO: 3, wherein the CDR is defined in accordance with the Kabat definition; and a light chain variable region (VL) that comprises a VL CDR1 of SEQ ID NO: 11, a VL CDR2 of SEQ ID NO: 12, and a VL CDR3 of SEQ ID NO: 13, wherein the CDR is defined in accordance with the Kabat definition.

2. An antibody or antigen binding fragment thereof that binds P-cadherin comprising:
a. A heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO:7, and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO:17.

3. An antibody or antigen binding fragment thereof that binds P-cadherin comprising:
a. A heavy chain comprising the amino acid sequence of SEQ ID NO:9, and a light chain comprising the amino acid sequence of SEQ ID NO:19.

4. An antibody drug conjugate comprising the formula
Ab-(L-(D) m ) n
or a pharmaceutically acceptable salt thereof; wherein
Ab is an antibody or antigen binding antigen binding fragment thereof according to claim 1 ;
L is a linker;
D is a drug moiety;
m is an integer from 1 to 8; and
n is an integer from 1 to 10.

5. The antibody drug conjugate of claim 4 , wherein said m is 1.

6. The antibody drug conjugate of claim 4 , wherein said n is 3 or 4.

7. The antibody drug conjugate of claim 4 , wherein the antibody or antigen binding fragment thereof (Ab) comprises a VH region comprising the amino acid sequence of SEQ ID NO:7 and a VL region comprising the amino acid sequence of SEQ ID NO:17.

8. The antibody drug conjugate of claim 4 , wherein said antibody or antigen binding fragment thereof comprises a heavy chain of SEQ ID NO: 9 and a light chain of SEQ ID NO: 19.

9. The antibody drug conjugate of claim 4 , wherein said linker (L) is derived from cross-linking reagents selected from the group consisting of N-succinimidyl 4-(maleimidomethyl) cyclohexanecarboxylate (SMCC), N-succinimidyl 4-(2-pyridyldithio)butanoate (SPDB), and 2,5-dioxopyrrolidin-1-yl 17-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-5,8,11,14-tetraoxo-4,7,10,13-tetraazaheptadecan-1-oate (CX1-1).

10. The antibody drug conjugate of claim 4 , wherein the drug moiety (D) is a maytansinoid.

11. The antibody drug conjugate of claim 10 , wherein the maytansinoid is N(2′)-deacetyl-N(2′)-(3-mercapto-1-oxopropyl)-maytansine (DM1) or N(2′)-deacetyl-N2-(4-mercapto-4-methyl-1-oxopentyl)-maytansine (DM4).

12. The antibody drug conjugate of claim 4 comprising the following formula:

wherein Ab is an antibody or antigen binding fragment thereof that binds P-cadherin comprising a VH CDR1 of SEQ ID NO: 1, a VH CDR2 of SEQ ID NO: 2, and a VH CDR3 of SEQ ID NO: 3, and a VL CDR1 of SEQ ID NO: 11, a VL CDR2 of SEQ ID NO: 12, and a VL CDR3 of SEQ ID NO: 13, wherein the CDR is defined in accordance with the Kabat definition; and n is an integer from 1 to 10; or a pharmaceutically acceptable salt thereof.

13. A pharmaceutical composition comprising the antibody, or antigen binding fragment thereof, of claim 1 and a pharmaceutically acceptable carrier.

14. A pharmaceutical composition comprising the antibody drug conjugate of claim 4 and a pharmaceutically acceptable carrier.

15. The pharmaceutical composition of claim 14 wherein said composition is prepared as a lyophilisate.

16. The pharmaceutical composition of claim 15 wherein said lyophilisate comprises the antibody drug conjugate, histidine, sucrose, and polysorbate 20.

17. The pharmaceutical composition of claim 16 wherein the composition comprises about 10 mg/mL of the antibody drug conjugate, 20 mM histidine, 240 mM sucrose, and 0.02% polysorbate 20.

18. The antibody or antigen binding fragment of claim 1 , wherein said antibody is a human or humanized antibody.

19. The antibody or antigen binding fragment of claim 1 , wherein said antibody is a monoclonal antibody.

20. The antibody or antigen binding fragment of claim 1 , wherein said antibody or antigen binding fragment is a single chain antibody (scFv).

21. A diagnostic reagent comprising the antibody or antigen binding fragment thereof according to claim 1 .

22. The diagnostic reagent of claim 21 , wherein the antibody or antigen binding fragment thereof is labeled with a radiolabel, a fluorophore, a chromophore, an imaging agent, or a metal ion.

Assignees

• Abrams Tinya
• Cohen Steven Bruce
• Damiano Jason
• Duerr Clemens
• Huber Thomas
• Menezes Daniel
• Miller Kathy
• Rendahl Katherine
• Rondeau Jean Michel Rene
• Novartis Ag

Inventors

• Abrams Tinya
• Cohen Steven Bruce
• Damiano Jason
• Dürr Clemens
• Huber Thomas
• Menezes Daniel
• Miller Kathy
• Rendahl Katherine
• Rondeau Jean-Michel Rene

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• G01N33/5759

  involving compounds localised on the membrane of tumour or cancer cells · CPC title

• C07K2317/55

  Fab or Fab' · CPC title

• C07K2317/24

  containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title

• A61K47/6849

  the antibody targeting a receptor, a cell surface antigen or a cell surface determinant · CPC title